Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366306 | 1.00 | CYP1A2 (0.42) | CYP1A2UCHL1PDE4BHDAC1HDAC6 | |
| SCHEMBL4359704 | 0.85 | CYP1A2 (0.48) | CYP1A2HDAC1HDAC6ERN1KDM4E | |
| SCHEMBL4359706 | 0.85 | CYP1A2 (0.48) | CYP1A2HDAC1HDAC6ERN1KDM4E | |
| SCHEMBL4362159 | 0.85 | CYP1A2 (0.41) | CYP1A2UCHL1PDE4BHDAC1HDAC6 | |
| SCHEMBL4362160 | 0.85 | CYP1A2 (0.41) | CYP1A2UCHL1PDE4BHDAC1HDAC6 | |
| SCHEMBL19284643 | 0.83 | PTPN1 (0.47) | CYP1A2UCHL1PDE4BHDAC1HDAC6 | |
| SCHEMBL28970129 | 0.79 | CYP1A2 (0.45) | CYP1A2PDE4BHDAC1HDAC6PDE4A | |
| SCHEMBL30239540 | 0.79 | UCHL1 (0.47) | UCHL1HDAC8MEN1KMT2A | |
| SCHEMBL16518060 | 0.75 | CYP1A2 (0.47) | CYP1A2UCHL1PDE4BHDAC1HDAC6 | |
| SCHEMBL13620324 | 0.73 | CTSD (0.32) | CYP1A2UCHL1PDE4BHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | CYP1A2 1061/4885UCHL1 27/4885PDE4B 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.